Institute of Good Manufacturing Practices India®

Global accredited training & certification provider

IGMPI Approvals & Accreditation : Approved by Quality Council of India (QCI) & Accredited Vocational Institution of Ministry of HRD, Government of India, Approved Training Institute of Food Safety and Standards Authority of India (FSSAI), Recognized by Department of Industrial Policy & Promotion, Ministry of Commerce & Industry, Government of India, An ISO 9001:2015 Certified Organisation registered under The Societies Registration Act,1860 Government of India Empanelled under Ministry of Horticulture and Food Processing, Government of Uttar Pradesh, Affiliated with Life Sciences and Food Industry Sector Skills Council (SSC)
Trusted by organizations & training participants in over 30 countries. Training | Certification | Education | Research

USFDA said Patanjali’s sharbat bottles contains different dietary, medical claims

22nd July 2019

According to the USFDA, the labels on Patanjali’s two sharbat bottles, sold within India, were found to be having “additional medicinal and dietary market claims” as compared to the ones meant for export to America. They also found out that the production and packaging area for exported products is separate from the domestic products.

The US food safety regulations are more stringent than Indian laws. If the company is found to be guilty of selling misbranded product in US, the USFDA can issue them a warning letter and can take serious actions like seize of whole batch, stopping the import, huge fine and even imprisonment of company officials.

Unit Ⅲ of Haridwar plant of Patanjali Ayurved Ltd. was inspected by the USFDA inspector last year. The inspector observed pigeons flying above the production equipment during Honey manufacturing. It was noticed that the production and packaging area is separate for Digestif manufacturing for export and domestic market. Inspector also found out that the firm’s laboratory personnel and batch records only “appear to follow” written operating procedures as they were not in operating mode during inspection.

Corrective actions should be followed by the company to avoid the USFDA actions.

For further enquiries, write to or call us on: +91 8587838177, +91 8130924488, 0120-2427175, 0120-4375280

Pharmaceuticals | Food | Clinical Research | Healthcare | Medical Coding | Medical Device | Nanotechnology | IPR

Placement testimonials: Our alumni are working with Fortune 500 and global Pharmaceutical, Food and healthcare giants like